Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Medicine and Health Sciences
Determination Of Novel Metabolites Of Therapeutic Agents Used In The Treatment Of Castration-Resistant Prostate Cancer, Mohammad Alyamani
Determination Of Novel Metabolites Of Therapeutic Agents Used In The Treatment Of Castration-Resistant Prostate Cancer, Mohammad Alyamani
ETD Archive
Despite an array of improved treatment options over the past decade, prostate cancer remains the second leading cause of cancer mortality for men in the United States. Abiraterone and galeterone are oral steroidal compounds that are used to treat metastatic castration-resistant prostate cancer (CRPC). Abiraterone blocks 17a-hydroxylase/17,20-lyase (CYP17A1), an enzyme required for androgen synthesis. Galeteron inhibits CYP17A1, blocks the androgen receptor (AR), and decreases AR protein levels. Both drugs share the same structure with endogenous androgens such as dehydroepiandrosterone, which are substrates for the enzyme, 3ß-hydroxysteroid dehydrogenase (3ßHSD). Metabolites of 3ßHSD undergo further metabolism to produce the AR ligand, testosterone …
Development Of A Testicular Cancer Vaccine, Roberto Aguilar Iii
Development Of A Testicular Cancer Vaccine, Roberto Aguilar Iii
ETD Archive
Testicular cancer mainly affects men between the ages of 20 and 35 but is the most common male neoplasm between the ages of 15 and 34. The National Cancer Institute (NCI) states that localized testicular cancer has a recurrence rate of 15-20% and tumors that are Sertoli or Leydig cell derived fail to respond to chemotherapy or radiation treatments. The recurrence rate may increase to 32% if at diagnosis the tumor is greater than 4 cm in size with invasion of the rete testes. To improve therapy for testicular cancer, we examined the usefulness of a testicular cancer vaccine. We …